These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37963701)

  • 1.
    Hanumunthadu B; Kanji N; Owino N; Ferreira Da Silva C; Robinson H; White R; Ferruzzi P; Nakakana U; Canals R; Pollard AJ; Ramasamy M;
    BMJ Open; 2023 Nov; 13(11):e072938. PubMed ID: 37963701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nontyphoidal salmonella disease: Current status of vaccine research and development.
    Tennant SM; MacLennan CA; Simon R; Martin LB; Khan MI
    Vaccine; 2016 Jun; 34(26):2907-2910. PubMed ID: 27032517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol for the challenge non-typhoidal
    Smith C; Smith E; Rydlova A; Varro R; Hinton JCD; Gordon MA; Choy RKM; Liu X; Pollard AJ; Chiu C; Cooke GS; Gibani MM
    BMJ Open; 2024 Jan; 14(1):e076477. PubMed ID: 38199617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal
    Micoli F; Rondini S; Alfini R; Lanzilao L; Necchi F; Negrea A; Rossi O; Brandt C; Clare S; Mastroeni P; Rappuoli R; Saul A; MacLennan CA
    Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10428-10433. PubMed ID: 30262653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine value profile for invasive non-typhoidal Salmonella disease.
    Martin LB; Tack B; Marchello CS; Sikorski MJ; Owusu-Dabo E; Nyirenda T; Mogasale V; Crump JA
    Vaccine; 2024 Jul; 42(19S1):S101-S124. PubMed ID: 39003017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-Like Receptor Activation by Generalized Modules for Membrane Antigens from Lipid A Mutants of Salmonella enterica Serovars Typhimurium and Enteritidis.
    Rossi O; Caboni M; Negrea A; Necchi F; Alfini R; Micoli F; Saul A; MacLennan CA; Rondini S; Gerke C
    Clin Vaccine Immunol; 2016 Apr; 23(4):304-14. PubMed ID: 26865597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of O-antigen delivered by Generalized Modules for Membrane Antigens (GMMA) vaccine candidates against nontyphoidal Salmonella.
    De Benedetto G; Alfini R; Cescutti P; Caboni M; Lanzilao L; Necchi F; Saul A; MacLennan CA; Rondini S; Micoli F
    Vaccine; 2017 Jan; 35(3):419-426. PubMed ID: 27998639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the Potential for Vaccination to Diminish the Burden of Invasive Non-typhoidal Salmonella Disease in Young Children in Mali, West Africa.
    Bornstein K; Hungerford L; Hartley D; Sorkin JD; Tapia MD; Sow SO; Onwuchekwa U; Simon R; Tennant SM; Levine MM
    PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005283. PubMed ID: 28182657
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Gasperini G; Massai L; De Simone D; Raso MM; Palmieri E; Alfini R; Rossi O; Ravenscroft N; Kuttel MM; Micoli F
    Front Cell Infect Microbiol; 2024; 14():1347813. PubMed ID: 38487353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a novel trivalent invasive non-typhoidal Salmonella outer membrane vesicles based vaccine against salmonellosis and fowl typhoid in chickens.
    Maiti S; Halder P; Banerjee S; Dutta M; Kumar Mukhopadhyay A; Dutta S; Koley H
    Immunobiology; 2022 Mar; 227(2):152183. PubMed ID: 35121180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerating clinical development of a live attenuated vaccine against
    McCann N; Emary K; Singh N; Mclean F; Camara S; Jones E; Kim YC; Liu X; Greenland M; Conlin K; Hill J; Verheul M; Robinson H; Angus B; Ramasamy MN; Levine MM; Pollard AJ
    BMJ Open; 2023 May; 13(5):e068966. PubMed ID: 37225278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgG Responses to Porins and Lipopolysaccharide within an Outer Membrane-Based Vaccine against Nontyphoidal
    Schager AE; Dominguez-Medina CC; Necchi F; Micoli F; Goh YS; Goodall M; Flores-Langarica A; Bobat S; Cook CNL; Arcuri M; Marini A; King LDW; Morris FC; Anderson G; Toellner KM; Henderson IR; López-Macías C; MacLennan CA; Cunningham AF
    mBio; 2018 Mar; 9(2):. PubMed ID: 29511082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The iNTS-GMMA vaccine: a promising step in non-typhoidal Salmonella vaccine development.
    Skidmore PD; Canals R; Ramasamy MN
    Expert Rev Vaccines; 2023; 22(1):918-920. PubMed ID: 37824701
    [No Abstract]   [Full Text] [Related]  

  • 15. Non-typhoidal Salmonella serovars associated with invasive and non-invasive disease in the Lao People's Democratic Republic.
    Le Thi Phuong T; Rattanavong S; Vongsouvath M; Davong V; Phu Huong Lan N; Campbell JI; Darton TC; Thwaites GE; Newton PN; Dance DAB; Baker S
    Trans R Soc Trop Med Hyg; 2017 Sep; 111(9):418-424. PubMed ID: 29342283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Anti-Bacterial Immunity against Systemic Infection by
    Fiorino F; Pettini E; Koeberling O; Ciabattini A; Pozzi G; Martin LB; Medaglini D
    Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34065899
    [No Abstract]   [Full Text] [Related]  

  • 18. Pathogenic signature of invasive non-typhoidal
    Piccini G; Montomoli E
    Hum Vaccin Immunother; 2020 Sep; 16(9):2056-2071. PubMed ID: 32692622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An association between decreasing incidence of invasive non-typhoidal salmonellosis and increased use of antiretroviral therapy, Gauteng Province, South Africa, 2003-2013.
    Keddy KH; Takuva S; Musekiwa A; Puren AJ; Sooka A; Karstaedt A; Klugman KP; Angulo FJ
    PLoS One; 2017; 12(3):e0173091. PubMed ID: 28264046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.